Brief: AN2 To Voluntarily Pause Enrollment In Phase 3 Part Of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole

AN2 Therapeutics

12/02/2024 11:50

Feb 12 (Reuters) - AN2 Therapeutics Inc  ANTX.O :
    * AN2 TO VOLUNTARILY PAUSE ENROLLMENT IN PHASE 3 PART OF
PHASE 2/3
PIVOTAL CLINICAL TRIAL EVALUATING EPETRABOROLE FOR
TREATMENT-REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG
DISEASE
    * AN2 THERAPEUTICS INC: ENROLLED PATIENTS ALLOWED TO
CONTINUE ON
STUDY
    * AN2 THERAPEUTICS INC: CONTINUES TO EXPECT TO ANNOUNCE
TOPLINE
DATA FROM PHASE 2 PART OF TRIAL IN SUMMER 2024
    * AN2 THERAPEUTICS INC: DECISION WAS NOT DUE TO SAFETY
CONCERNS
    * AN2 THERAPEUTICS INC - VOLUNTARY DECISION TO PAUSE
ENROLLMENT IN
PHASE 3 PART OF STUDY WILL PROVIDE US OPPORTUNITY TO FURTHER
EVALUATE STUDY DATA
    * AN2 THERAPEUTICS : PAUSE INSTITUTED FOLLOWING BLINDED
AGGREGATE
ANALYSIS OF PHASE 2 STUDY WHICH SHOWED POTENTIALLY LOWER THAN
EXPECTED EFFICACY

Source text for Eikon:  ID:nBw4XMBQ6a 
Further company coverage:  ANTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))